Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALXN2050 + rifampin
- Development stage
- Discontinued
- Lead developer
- Alexion Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ALXN2050 (vemircopan) is an investigational oral small molecule that acts as a selective inhibitor of *complement factor D*, a key enzyme in the alternative complement pathway. ALXN2050 is under development for the treatment of autoimmune diseases, specifically generalized myasthenia gravis (gMG) and kidney diseases such as lupus nephritis and IgA nephropathy. The combination "ALXN2050 + rifampin" refers to the concomitant administration of ALXN2050 and rifampin, which may be studied for drug-drug interactions or to assess the effect of rifampin (a known inducer of drug-metabolizing enzymes) on the pharmacokinetics of ALXN2050. Rifampin itself is an approved antibiotic used primarily for tuberculosis and acts as a strong inducer of cytochrome P450 enzymes, affecting the metabolism of many drugs.
- Other names
- ALXN 2050ALXN2050ALXN-2050vemircopan
02
Targets
CFD (Complement Factor D)
Beyond the preview
Go deeper on ALXN2050 + rifampin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALXN2050 + rifampin.